mpMRI

DIAGNOSTIC_TEST11 trials

Sponsors

National Cancer Institute (NCI), Lille Catholic University, Icahn School of Medicine at Mount Sinai, Torben Brøchner Pedersen, Mansoura University

Conditions

Bladder CancerCancer Of ProstateClinically Significant Portal HypertensionFluorocholineGastric Cancer, Gastroesophageal Junction CancerKidney CancersNeoplasms of ProstatePortal Hypertension

Early Phase 1

Assessment of Renal Function by Multiparametric MRI

CompletedNCT06407375

University of ZurichRenal Impairment

Start: 2023-07-25End: 2025-05-09Updated: 2025-12-09

Phase 1

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

CompletedNCT03388619

National Cancer Institute (NCI)Cancer Of Prostate, Neoplasms of Prostate, Prostate Cancer +2

Start: 2018-01-17End: 2025-12-04Updated: 2026-08-28

Phase 2

Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

CompletedNCT02430480

National Cancer Institute (NCI)Prostate Cancer

Start: 2015-06-03End: 2024-06-11Updated: 2025-07-16

Unknown Phase

Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies

TerminatedNCT02971995

Lille Catholic UniversityFluorocholine, Positron-Emission Tomography, Prostatic Neoplasm

Start: 2014-12-01End: 2016-10-01Updated: 2026-06-12

Assessment of Portal Hypertension With Multiparametric MRI

CompletedNCT03436550

Icahn School of Medicine at Mount SinaiClinically Significant Portal Hypertension, Portal Hypertension

Start: 2018-03-20End: 2022-07-19Updated: 2023-03-06

Predicting Prostate Biopsy Results With Biomarkers and mpMRI.

CompletedNCT03730324

Torben Brøchner PedersenProstate Cancer

Start: 2018-11-05End: 2022-06-01Updated: 2023-03-23

Comprehensive Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Non Muscle-invasive Bladder Tumor; Can it Replace Second Look Biopsy? A Prospective Study

Mansoura UniversityBladder Cancer

Start: 2019-04-01End: 2020-06-01Target: 100Updated: 2019-04-12

Multicentric Evaluation of the True Negative Predictive Value of Multiparametric MRI for the Detection of Prostate Cancer Using Cystoprostatectomy Specimen as Reference

Institut Paoli-CalmettesProstate Cancer

Start: 2020-10-01End: 2022-12-01Target: 150Updated: 2020-07-28

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

RecruitingNCT04692675

National Cancer Institute (NCI)Prostate Cancer

Start: 2022-11-18End: 2031-09-01Target: 508Updated: 2026-08-27

MRI and CT in Gastroesophageal Junction or Upper Gastric Adenocarcinoma

Active, not recruitingNCT06640153

The First Affiliated Hospital with Nanjing Medical UniversityGastric Cancer, Gastroesophageal Junction Cancer

Start: 2024-08-21End: 2027-08-24Target: 100Updated: 2024-10-15

Tumor Heterogeneity of Renal Tumors Assessed by Multiparametric MRI With Direct Radiological-histopathological Correlation: an Explorative Study

CompletedNCT07713654

University of ZurichKidney Cancers

Start: 2023-08-02End: 2025-07-10Updated: 2026-07-20

Related Papers

Multiparametric MRI for Diagnosing Clinically Significant Portal Hypertension and Predicting Liver Decompensation.

2025-11-01

Localized high-risk prostate cancer harbors an androgen receptor activity–low subpopulation susceptible to HER2 inhibition

Journal of Clinical Investigation2025-09-041 citations

Abstract 304: Profiling the acute effects of androgen receptor inhibition in hormone-sensitive prostate cancer

Cancer Research2025-04-211 citations

Association of localized high-risk prostate cancer (PC) and an androgen receptor low subpopulation susceptible to HER2 inhibition.

Journal of Clinical Oncology2025-02-10

Castration Levels of Testosterone Results in Atrophy of Androgen-sensitive Perineal Muscles: A Potential Biomarker for Male Hypogonadism.

2024-10-18

Abstract B010: A novel systemic methodology for mapping the clonal architectures of human prostate tumors that develop resistance to androgen receptor (AR)-targeted therapy

Cancer Research2023-06-02

Abstract A004: Investigating the function of <i>ZFHX3</i> in hormone sensitive prostate cancer initiation and treatment resistance

Cancer Research2023-06-02

Abstract B021: Examining the role of HER2 signaling in promoting prostate cancer proliferation in an androgen receptor-low environment

Cancer Research2023-06-02

Abstract 618: The morphologic effects of treatment with neoadjuvant enzalutamide and androgen deprivation therapy in high risk prostatic cancer: What the pathologist needs to know

Cancer Research2020-08-15

A tale of lineage plasticity: Intense neoadjuvant testosterone lowering therapy in localized prostate cancer (PCa) harboring high-risk genomic signatures.

Journal of Clinical Oncology2020-02-19

Multiple primary prostate tumors with differential drug sensitivity.

Journal of Clinical Oncology2020-02-19

Abstract 2510: Combining genetic and histopathologic features to predict response to anti-androgen therapy in aggressive prostate cancer

Cancer Research2019-07-01

Abstract 2510: Combining genetic and histopathologic features to predict response to anti-androgen therapy in aggressive prostate cancer

Molecular and Cellular Biology / Genetics2019-07-01

mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy.

2019-04-156 citations

A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI).

Journal of Clinical Oncology2019-03-011 citations

Molecular and imaging correlates of exceptional pathologic response to neoadjuvant ADT plus enzalutamide.

Journal of Clinical Oncology2019-03-01

Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses.

Journal of Clinical Oncology2018-05-20

PD14-05 NEOADJUVANT ENZALUTAMIDE AND ANDROGEN DEPRIVATION IN HIGH-RISK PROSTATE CANCER: INITIAL IMAGING AND SURGICAL FINDINGS FROM A PHASE II CLINICAL TRIAL

The Journal of Urology2018-04-01

Neoadjuvant enzalutamide and androgen deprivation therapy for high-risk prostate cancer: Early results from a feasibility trial.

Journal of Clinical Oncology2018-02-201 citations

Molecular and histopathologic correlates of imaging and biological responses to neoadjuvant GnRH agonist plus enzalutamide for high risk prostate cancer.

Journal of Clinical Oncology2018-02-20